Martin Leon
Dr. Leon received his medical degree from the Yale School of Medicine and completed his internal medicine internship, residency and cardiology fellowship at the Yale-New Haven Hospital. He is currently a Professor of Medicine at Columbia University’s Center for Interventional Vascular Therapy (CIVT) at New York-Presbyterian Hospital/Columbia University Medical Center and serves on the Executive Board of the New York-Presbyterian/Columbia Heart Valve Center. Marty was previously the Director of Cardiovascular Research and Education at the Lenox Hill Hospital, as well as the Director of Clinical Research at the Washington Cardiology Center.
Marty was the Founder of the Cardiovascular Research Foundation (CRF) in New York City and is currently CRF’s Co-Director of the Medical Research and Education Division. He founded and directed Transcatheter Cardiovascular Therapeutics (TCT), dedicated to interventional cardiovascular medicine, which celebrated its 28th anniversary last year. A distinguished pioneer in interventional cardiovascular medicine, Dr. Leon has been the national Principal Investigator for multiple landmark clinical trials, including STRESS, STARS, Gamma-one, SIRIUS, ENDEAVOR, and, most recently, the PARTNER trial.
Declaration of interest
| Function | Company |
|---|---|
| Information not available at the time of editing |
Latest contributions
TAVI vs. surgery - Are the latest long-term data creating a dilemma for aortic stenosis patients?
21 May 2026 – From EuroPCR 2026
This session critically evaluates the latest long-term data comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). It explores differing perspectives between surgeons and interventional cardiologists regarding valve durability and lifetime management, fostering a high-quality debate to achieve consensus within Heart Team discussions...
ARTICA: Coronary revascularisation in patients undergoing TAVI - an individual patient data meta-analysis of 4 randomised trials
21 May 2026 – From EuroPCR 2026
At EuroPCR 2026, Martin Leon and Roberto Scarsini review ARTICA, a patient-level meta-analysis combining data from the ACTIVATION, NOTION-3, FAITAVI, and TCW randomised trials.
The analysis included 1,050 patients with severe aortic stenosis and concomitant coronary artery disease and compared three management strategies: medical therapy, angiography-guided PCI,...
Spotlight - TAVI durability: contemporary evidence and future directions
21 May 2026 – From EuroPCR 2026
Focusing on TAVI durability, this session reviews recent clinical evidence from randomized trials and large registries, examining procedural and device-related factors influencing long-term valve performance. It also discusses challenges in follow-up and implications for future trial designs and device monitoring.
Modern risk prediction in TAVI
21 May 2026 – From EuroPCR 2026
This session examines modern risk prediction models in transcatheter aortic valve implantation (TAVI). It presents novel scoring systems, the prognostic significance of cardiac damage extent and progression, and the impact of multivalvular disease, enhancing patient stratification and outcome prediction.
MagicTouch sirolimus-coated balloon for coronary artery disease and peripheral artery disease treatment: where evidence meets experience
20 May 2026 – From EuroPCR 2026
This session examines the clinical evidence and experiential insights regarding the MagicTouch sirolimus-coated balloon (SCB) for treating coronary and peripheral artery disease. It reviews long-term comparative data versus paclitaxel-coated balloons, application techniques, integration into current practices, and findings from major trials such as SIRONA and SIMPLE-DM,...
Major Late-Breaking Trials from EuroPCR 2026
20 May 2026 – From EuroPCR 2026
This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.
TAVI: head-to-head trials
20 May 2026 – From EuroPCR 2026
This session presents head-to-head comparisons of TAVI devices from recent randomized trials and registries. Highlights include three-year outcomes from the SMART trial, two-year data from the LANDMARK trial on contemporary valves, comparisons of intra- and supra-annular self-expanding valves, evaluations in large annuli, the ALLEGRA trial focusing...
TAVI and coronary artery disease: we need the COMPLETE answer!
19 May 2026 – From EuroPCR 2026
Addressing the intersection of transcatheter aortic valve implantation (TAVI) and coronary artery disease, this session reviews contemporary surgical and interventional literature to elucidate current practices. It underscores the need for a large international randomized controlled trial to provide definitive guidance for managing patients with concomitant aortic...
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
TAVI today and tomorrow: international trends and future direction
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...
Late-breaking trials of PCR Tokyo Valves 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral...
Pills and pumps: targeting heart failure before and after surgical and transcatheter valve interventions
18 Nov 2025 – From PCR London Valves 2025
This session examines the integrated role of heart failure therapies in the peri- and post-procedural management of patients undergoing surgical and transcatheter valve interventions. It reviews current and emerging clinical trial data, discusses identifying high-risk patients, and explores advanced modalities such as cardiac resynchronization and circulatory...
TAVI in 2025: transforming care with the new valvular heart disease guidelines
18 Nov 2025 – From PCR London Valves 2025
This session explores how the 2025 valvular heart disease guidelines are transforming the landscape of TAVI care and clinical decision-making. It highlights the paradigm shift in managing severe aortic stenosis and provides a global perspective on the challenges and strategies for managing an expanding TAVI patient...
Newsflash: the best of TCT 2025
17 Nov 2025 – From PCR London Valves 2025
Stay informed with the latest highlights and key advancements from TCT 2025. This session distills the most impactful clinical data, innovative techniques, and emerging trends presented at the conference, providing essential updates for interventional cardiology practice.
Late-breaking evidence in structural and coronary interventions - Part 2
16 Nov 2025 – From PCR London Valves 2025
This session presents the latest data from pivotal late-breaking trials in interventional cardiology. Highlights include one-year results from the ADALA trial, first-in-man use of the Vivasure PerQseal Elite for large hole arterial closure, two-year outcomes of the DragonFly system in China, six-month European outcomes, and insights...
The impact of paravalvular leak, permanent pacemaker implantation and the planning for reinterventions on lifetime management in TAVI patients
22 May 2025 – From EuroPCR 2025
How do paravalvular leak, pacemaker implantation and reintervention planning shape lifetime outcomes in TAVI patients?
This session examines these crucial aspects through the case of a 77-year-old male with bicuspid aortic valve stenosis, HFpEF and multiple comorbidities, including diabetes, obesity and sleep apnoea.
Follow the discussion to understand...
Hotline TAVI 1: extended analysis of the randomised trials
21 May 2025 – From EuroPCR 2025
Gain comprehensive insights from extended analyses of randomized TAVI trials. This session reviews five-year UK TAVI outcomes, cardiac damage evolution in asymptomatic aortic stenosis, one-year results from the LANDMARK trial, and three-year comparisons of balloon-expandable valves, highlighting critical clinical implications.
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier
20 May 2025 – From EuroPCR 2025
This EuroPCR 2025 session delivers a comprehensive update on the MagicTouch sirolimus-coated balloon (SCB) and its expanding role in treating both coronary and peripheral artery disease (CAD/PAD). The session covers the extensive clinical trial program supporting MagicTouch as a versatile treatment option across multiple indications. It...
Asymptomatic severe aortic stenosis: Will these trials change my practice?
16 May 2024 – From EuroPCR 2024
This session, in collaboration with Partners in Learning, explores the emerging evidence on the use of transcatheter aortic valve implantation (TAVI) in patients with asymptomatic severe aortic stenosis. It covers data from registries and randomized controlled trials, the current guideline recommendations, and the potential impact of...
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
TEER for primary mitral regurgitation - LIVE case
15 May 2024 – From EuroPCR 2024
A 76-year-old male, with previous CABG in 2015, hypertension, diabetes, and pulmonary hypertension (WHO2), presented with severe symptomatic primary MR (P3 flail).
The operators implanted 1 MitraClip (XTW) step-by-step, from the transseptal puncture to the closure, guided by TEE echo and under general anaesthesia, via the venous...
Tribute to Alain Cribier
14 May 2024 – From EuroPCR 2024
Asymptomatic severe aortic stenosis, how will new evidence change our practice?
15 May 2024 – From EuroPCR 2024
Victoria Delgado and Martin Leon discuss how to treat patients with asymptomatic severe aortic stenosis at an earlier stage and how current trials may change our practice in the future and broaden the indications.
This interview was filmed at EuroPCR 2024: see more videos here.
First report of an IDE pivotal study of a dedicated splitting device during TAVR
15 May 2024 – From EuroPCR 2024
Watch this interview in which Christopher Cook hosts Martin Leon to discuss pivotal study data on the ShortCut dedicated leaflet splitting device. They revisit the unmet clinical need for leaflet splitting during TAVR: transcatheter valve failures, noting that transcatheter valve failures could surpass surgical bioprosthetic valve failures...
PARTNER 3 Low-Risk trial: 5-year insights on TAVI vs. SAVR outcomes
Alex Sticchi interviews Martin Leon about the five-year clinical and echocardiographic outcomes from the PARTNER 3 Low-Risk randomized trial, presented at the #TCT23 Congress.
The analysis reveals comparable outcomes for TAVI and SAVR, with nuanced differences favouring each approach. Prof. Leon emphasizes the importance of long-term data...
TAVI: From simple to complex - LIVE case
20 Nov 2023 – From PCR London Valves 2023
This session explores two clinical cases, providing valuable insights into the essential components of a straightforward and efficient TAVI procedure. Find out more about the application of innovative devices to broaden the scope of aortic valve intervention, facilitating their integration into Heart Team discussions and daily...
!!!NEWSFLASH!!! Long-term outcomes of the TAVI low risk trials - from headlines to clinical practice
20 Nov 2023 – From PCR London Valves 2023
Join this session to navigate through the long-term outcomes of TAVI low-risk trials (Partner 3, Evolut Low Risk...), to enhance your ability to synthesize and interpret clinical evidence and to learn how to seamlessly integrate these insights into your Heart Team's daily clinical practice.
Top Innovations
20 Nov 2023 – From PCR London Valves 2023
Discover the future of cardiac care with these 3 top innovations! ARTERY, revolutionizing structural heart treatment, Vesalius Transfemoral DMR Repair, combining chordal and annular support in one-transfemoral device, and Approxima, a right ventricular reshaping device, offering a fresh perspective on tricuspid regurgitation.
